The dependence of breast cancer on CDK4/6 and its binding partner cyclin D1 for progression through the G1/S phase of the cell cycle has made breast cancer a prime target for the implementation of CDK4/6 inhibitor-based therapy [8]. The gene discussed is CCND1; the disease is breast cancer.